A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein called Glypican 3 (GPC3). Researchers want to find the best dose of BAY 3547926 for people with advanced HCC and look at the way the body absorbs and distributes the drug. The study drug, BAY 3547926, delivers a radioactive agent to cancer cells. The radioactive agent emits radiations which can damage the cancer cells and cause them to die. These radiations travel a sm

Trial Details

NCT ID

NCT06764316

Phase

PHASE1

Sponsor

Bayer

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

BAY 3547926
BAY 3547922
BAY 3713391
BAY 3713389

Locations (sample)

Dothan, Alabama, United States|31.22323,-85.39049
Duarte, California, United States|34.13945,-117.97729
Orlando, Florida, United States|28.53834,-81.37924
Nashville, Tennessee, United States|36.16589,-86.78444
Edegem, Antwerp, Belgium|51.15662,4.44504

Key Eligibility Criteria

Locally advanced or metastatic and/or unresectable HCC (hepatocellular carcinoma) with histological or cytological confirmation, or non-invasive di…
Demonstrated positive centrally confirmed GPC3 expression by immunohistochemistry (IHC) on tumor sample.
Disease not amenable to, or progressive disease after, curative surgery and/or locoregional therapies of established efficacy such as resection, lo…
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →